Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;101:2721-2726

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oudijk, M. A.
Right arrow Articles by Meijboom, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oudijk, M. A.
Right arrow Articles by Meijboom, E. J.
Related Collections
Right arrow Pediatric and congenital heart disease, including cardiovascular surgery
Right arrow Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2000;101:2721.)
© 2000 American Heart Association, Inc.


Clinical Investigation and Reports

Sotalol in the Treatment of Fetal Dysrhythmias

Martijn A. Oudijk, MD; Maaike M. Michon, MD; Charles S. Kleinman, MD, PhD; Livia Kapusta, MD; Philip Stoutenbeek, MD, PhD; Gerard H. A. Visser, MD, PhD; Erik J. Meijboom, MD, PhD

From the Division of Pediatric Cardiology and Department of Obstetrics, University Medical Center, Utrecht, the Netherlands (M.A.O., M.M.M., P.S., G.H.A.V., E.J.M.); the Division of Pediatric Cardiology, Yale New Haven Hospital, Yale University School of Medicine, New Haven, Conn (C.S.K.); and the Children’s Heart Center, University Hospital Nijmegen, Nijmegen, the Netherlands (L.K.).

Correspondence to Erik J. Meijboom, MD, PhD, Department of Cardiology, University Medical Center, KG 01.3190/PO Box 85090, 3508 AB, Lundlaan 6, 3584 EA, Utrecht, The Netherlands. E-mail e.meijboom{at}azu.nl

Background—Fetal tachycardia may cause hydrops fetalis and lead to fetal death. No unanimity of opinion exists regarding the optimum treatment. This study evaluates our experience with transplacental sotalol therapy to treat fetal tachycardias in terms of safety and efficacy.

Methods and Results—The charts of 21 patients who were treated with sotalol for fetal tachycardia were reviewed. Ten fetuses had atrial flutter (AF), 10 had supraventricular tachycardia (SVT), and 1 had VT. Hydrops fetalis was present in 9 fetuses. Drug treatment was successful in establishing sinus rhythm in 8 of 10 fetuses with AF and in 6 of 10 fetuses with SVT. The mortality rate in this study was 19% (4 of 21 fetuses; 3 had SVT and 1 had AF); 3 deaths occurred just days after the initiation of sotalol therapy, and 1 occurred after a dosage increase. At birth, tachycardia was present in 6 infants. Two patients who converted to sinus rhythm in utero suffered from neurologic pathology postnatally.

Conclusions—Fetal tachycardia is a serious condition in which treatment should be initiated, especially in the presence of hydrops fetalis. The high success rate in fetuses with AF suggests that sotalol should be considered a drug of first choice to treat fetal AF. The low conversion rate and the fact that 3 of the 4 deaths in this study occurred in fetuses with SVT indicate that the risks of sotalol therapy outweigh the benefits in this group and that sotalol should, therefore, be limited in the treatment of fetal SVT.


Key Words: tachycardia • arrhythmia • maternal-fetal exchange • sotalol • hydrops fetalis




This article has been cited by other articles:


Home page
NeoReviewsHome page
H. R. Singh, S. Garekar, M. L. Epstein, and T. L'Ecuyer
Neonatal Supraventricular Tachycardia (SVT)
NeoReviews, July 1, 2005; 6(7): e339 - e350.
[Full Text] [PDF]


Home page
CirculationHome page
J. F. Strasburger, B. F. Cuneo, M. M. Michon, N. L. Gotteiner, B. J. Deal, S. N. McGregor, M. A. Oudijk, E. J. Meijboom, L. Feinkind, M. Hussey, et al.
Amiodarone Therapy for Drug-Refractory Fetal Tachycardia
Circulation, January 27, 2004; 109(3): 375 - 379.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. A. Oudijk, J. M. Ruskamp, F. F. T. Ververs, E. B. Ambachtsheer, P. Stoutenbeek, G. H. A. Visser, and E. J. Meijboom
Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics
J. Am. Coll. Cardiol., August 20, 2003; 42(4): 765 - 770.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
M Krapp, T Kohl, J M Simpson, G K Sharland, A Katalinic, and U Gembruch
Review of diagnosis, treatment, and outcome of fetal atrial flutter compared with supraventricular tachycardia
Heart, August 1, 2003; 89(8): 913 - 917.
[Abstract] [Full Text] [PDF]